Knight Therapeutics Inc (04K F) stock market data APIs
€3.6711
0(0%)
as of March 25, 2025
Knight Therapeutics Inc Financial Data Overview
Knight Therapeutics Inc. operates as a specialty pharmaceutical company that focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing pharmaceutical products in Canada and Latin America. The company was founded in 2014 and is based in Montreal, Canada. It operates in additional locations in Latin America, such as Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Mexico, Paraguay, Peru, and Uruguay.
Prev. Close
3.6711
Open
3.6711
High
3.6711
Low
3.6711
52 wk Range
3.4-4.12
Market Cap
372 M
P/E Ratio
122
Shares Outstanding
100 M
Revenue
371 M
Beta
0.42
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Knight Therapeutics Inc data using free add-ons & libraries
Get Knight Therapeutics Inc Fundamental Data
Knight Therapeutics Inc Fundamental data includes:
- Net Revenue: 371 M
- EBITDA: 55 957 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-03-19
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Knight Therapeutics Inc News
New
Knight Therapeutics Enters into Exclusive License Agreement with Amneal Pharmaceuticals for IPX203
Knight Therapeutics MONTREAL, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has e...
Knight Therapeutics Announces Product Launch for IMVEXXY® in Canada
Knight Therapeutics MONTREAL, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch o...
Knight Therapeutics Enters into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree® (viloxazine) in Canada
Knight Therapeutics MONTREAL, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has e...
Knight Therapeutics Reports Third Quarter 2023 Results
Knight Therapeutics - Achieved Record Nine-month Revenues and Adjusted EBITDA MONTREAL, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leadi...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
